Ｐａｇｅ 142574 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼EMEA Recommedns a N EnladsIdeanna 08/7/15(火) 1:37 ─────────────────────────────────────── ■題名 ： EMEA Recommedns a N ■名前 ： EnladsIdeanna <adfsg4@googlemail.com> ■日付 ： 08/7/15(火) 1:37 ■Ｗｅｂ ： http://google.com/uutlda -------------------------------------------------------------------------
| LONDON, June 17, 2008-The European Medicines power (EMEA) has recommended updating the produce report for epoetin-containing medicines with a new inmdication for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients hardship cancer. Epoetin-containing emdicines are indicated in patients with persitsentincompetent and foir the treatment of anaemmia in symptomatic patients with non-myeloid growths receiving chemotherapy. The instrumwntality痴 cabinet for sanative Products for sympathetic Use (CHMP) had noticeed new details from studies that showed anincreased endanger of growth achat levitra generique devel opment, venous thromboembolism and shorter all- inclusive survival in cancer patients who admitd epoetins compared to patients who did not admit them. Following this rehashing, the CHMP cnocluded, at ist June 2008 conference, that the gains of epoetins persist surpass their hazards in the approved indications. on the other hand, in cancer patients with a reasonably covet enthusiasm-expecancy, the improge of using epeotins does not surpass the endanger growth ascension and hsorter all-inclusive survival and consequently the cabinet concluded that in these patients anamia should be corrected with blood transfusions. |